Arcturus Therapeutics Holdings Inc.
ARCT
$6.75
$0.162.43%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.15M | 28.30M | 29.38M | 22.77M | 41.67M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.15M | 28.30M | 29.38M | 22.77M | 41.67M |
| Cost of Revenue | 3.34M | 29.58M | 34.89M | 43.78M | 4.40M |
| Gross Profit | 13.81M | -1.28M | -5.51M | -21.01M | 37.28M |
| SG&A Expenses | 10.40M | 10.34M | 11.32M | 12.38M | 13.28M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 33.66M | 39.92M | 46.21M | 56.16M | 52.41M |
| Operating Income | -16.51M | -11.62M | -16.83M | -33.39M | -10.74M |
| Income Before Tax | -13.45M | -9.18M | -14.08M | -30.01M | -7.12M |
| Income Tax Expenses | -- | 4.00K | -- | -4.00K | -217.00K |
| Earnings from Continuing Operations | -13.45M | -9.18M | -14.08M | -30.01M | -6.90M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -13.45M | -9.18M | -14.08M | -30.01M | -6.90M |
| EBIT | -16.51M | -11.62M | -16.83M | -33.39M | -10.74M |
| EBITDA | -15.75M | -10.84M | -16.03M | -32.58M | -9.83M |
| EPS Basic | -0.49 | -0.34 | -0.52 | -1.11 | -0.26 |
| Normalized Basic EPS | -0.31 | -0.21 | -0.32 | -0.69 | -0.16 |
| EPS Diluted | -0.49 | -0.34 | -0.52 | -1.11 | -0.26 |
| Normalized Diluted EPS | -0.31 | -0.21 | -0.32 | -0.69 | -0.16 |
| Average Basic Shares Outstanding | 27.19M | 27.13M | 27.11M | 27.00M | 27.06M |
| Average Diluted Shares Outstanding | 27.19M | 27.13M | 27.11M | 27.00M | 27.06M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |